Pipeline

RGN6024

RGN6024 development pipeline: discovery through IND-enabling studies for brain metastases and high-grade glioma

RGN6024 is an oral, twice-daily small molecule that crosses the blood-brain barrier by design and is not removed by the efflux pump. It is being developed for solid tumors and the metastases they spread, including metastases that reach the brain, and for high-grade glioma. Efficacy models to date are in small cell lung cancer and in glioblastoma.